GlassScriptPhysician profile
Fred S Revoredo
NPI 1669588422
$31,740.94
in general payments reported to CMS, 2019-2025
50 companies · $6,770 in 2025
The $6,770 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,290 · 2020: $2,939 · 2021: $4,849 · 2022: $4,230 · 2023: $3,674 · 2024: $4,989 · 2025: $6,770.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Travel and Lodging: $809.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,624.31 |
| Travel and Lodging | $809.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,140.49 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $3,572.97 | 2020-2025 | |
| Amgen INC. | $3,362.80 | 2019-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $3,198.85 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $2,104.73 | 2019-2025 | Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,804.46 | 2019-2025 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $1,503.66 | 2019-2025 | |
| Medtronic, INC. | $1,454.62 | 2025 | Minimed 780g |
| Merck Sharp & Dohme LLC | $1,000.99 | 2019-2025 | Verquvo, Capvaxive, Steglatro |
| Allergan, INC. | $947.99 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $756.04 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $597.22 | 2021-2024 | |
| Astellas Pharma US INC | $525.97 | 2019-2024 | Myrbetriq, Veozah |
| Amarin Pharma, INC. | $522.75 | 2019-2022 | |
| Pfizer INC. | $466.21 | 2019-2025 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fred Revoredo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.